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Paratuberculosis (PTB) is an enteritis of ruminants that 
involves infection with Mycobacterium avium subspecies 
paratuberculosis (MAP) generally shortly after birth through 
ingestion of bacteria shed in the feces of infected animals or 
colostrum from and infected dam. Affected cattle have a long 
(>2 years) subclinical phase prior to the emergence of clini-
cal signs including persistent diarrhea, weight loss, and 
decreased milk production.1,2 The emergence of the clinical 
phase of the disease is characterized by a transition of Th1 
cell-mediated immune responses to Th2 immune responses.3 
This shift in immune regulation results in alterations in the 
composition of the gastrointestinal (GI) flora,4 severe granu-
lomatous enteritis,5 and liver damage.6,7
Proteomics,8,9 metabolomics,10 transcriptomics,11,12 and 
microRNA13,14 studies of PTB have supported an altered 
immune response in infected cattle. Proteomics studies have 
reported an induction of acute phase reactants in the serum of 
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Abstract
Objectives: Bovine paratuberculosis is a devastating infection with Mycobacterium avium subspecies paratuberculosis that 
ultimately results in death from malnutrition. While the infection is characterized by a long (2–4 years) subclinical phase 
with immune activation, ultimately host defense mechanisms fail and the bacteria spread from the small intestine to other 
organs. Since both the gastrointestinal tract and liver are essential for the biosynthesis of structural glycerophospholipids, we 
investigated the circulating levels of these lipids in field infections and experimentally infected cattle.
Methods: Serum lipidomics of control and M. avium subspecies paratuberculosis–infected cattle were performed utilizing 
high-resolution mass spectrometry.
Results: In M. avium subspecies paratuberculosis–positive cattle, demonstrating clinical signs, we monitored large decreases 
in the levels of circulating phosphocholine-containing lipids. These included phosphatidylcholines, choline plasmalogens, and 
sphingomyelins. Next, we monitored the time course of these lipid alterations in experimentally infected calves and found 
that altered lipid levels were only detected in cattle with clinical signs of infection.
Conclusions: Our data indicate that altered availability of choline-containing lipids occurs late in the disease process and is 
most likely a result of malnutrition and altered biosynthetic capacities of the liver and gastrointestinal tract. Alterations in the 
bioavailability of these critical structural lipids presumably contributes to the demise of M. avium subspecies paratuberculosis–
infected cattle. In light of increasing concern that M. avium subspecies paratuberculosis may be a zoonotic bacterium that 
contributes to the development of Crohn’s disease and multiple sclerosis, our data also have human clinical relevance.
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infected cattle8 further supporting altered liver function in 
PTB. In contrast, there have not been any studies of the lipi-
dome in PTB, except for a transcriptomics study that detected 
altered enzyme function regulating cholesterol metabo-
lism.15,16 Since both the liver and GI epithelium are important 
sources of glycerophospholipids17,18 and are compromised in 
PTB, we undertook a non-targeted high-resolution mass 




Serum and fecal samples were submitted from clinical cases 
by the practitioners for diagnosis of MAP. Enzyme-linked 
immunosorbent assay (ELISA) (IDEXX MAP ELISA Ab 
Test kit, Westbrood, Maine) on serum samples and real-time 
polymerase chain reaction (PCR) assay (rt-PCR) (VetMAX™-
Gold MAP Detection Kit, Thermofisher scientific, Waltham, 
Massachusetts) on fecal samples were carried out by using 
commercial kits. All testing was performed at the University 
of Kentucky Veterinary Diagnostic Laboratory (UKVDL), a 
fully accredited laboratory by American Association of 
Veterinary Laboratory Diagnosticians (AAVLD). Serum and 
fecal samples from three MAP-negative and three MAP- pos-
itive cattle were stored at −80oC prior to analyses. The cycle 
threshold (Ct) of rt-PCR is used as an estimate of the amount 
of MAP DNA in the fecal material and gives a general idea 
about shedding status of the animal. The Ct was used as an 
estimate of the amount of MAP DNA in the fecal material. 
Generally, the lower the number, the more DNA in the fecal 
material. MAP DNA can then be correlated to the number of 
organisms shed in the fecal material as per the United States 
Department of Agriculture (USDA) guidelines: <25 Ct = Very 
Heavy Fecal Shedder; <30 Ct = Heavy Fecal Shedder; <33 
Ct = Moderate Fecal Shedder; <36 Ct = Light Fecal Shedder; 
<40 Ct = Suspect Fecal Shedder. The three positive cattle 
were heavy shedders. They were angus cattle from different 
farms and were approximately 2 years of age.
While the pilot study included only three animals, these 
were confirmed MAP-positive cattle that also demonstrated 
overt clinical signs. Hence, while the N was small, it was 
anticipated to be able to detect any robust alterations in the 
serum lipidome.
Cattle: validation study
For the validation study, field samples from 12 MAP-
negative cattle and 12 MAP-positive (by ELISA) cattle with 
overt signs (excessive diarrhea and weight loss) of Johne’s 
disease (>2 years old) were examined. The samples came 
from different farms to the University Veterinary Diagnostic 
Laboratory. The cattle were mainly 2- to 2.5-year-old angus. 
Both serum and fecal MAP DNA analyses and clinical crite-
ria were utilized as described above.
The N of 12 for the validation study was based on our 
prior experience with monitoring the effects of bacterial 
infections on the host lipidome. In addition, this was a real-
world study in that the samples were submitted to a central 
Veterinary Diagnostic Laboratory from different farms.
Cattle: time course study (experimental infection)
To monitor the time course of lipid changes, six control 
calves and seven experimentally infected calves9 were moni-
tored from month 0 to month 16. Two of the calves devel-
oped clinical signs of Johne’s disease by month 16. The 
samples we examined were from the high-dose animals in 
the metabolomics study conducted by De Buck et al.9 The 
high-dose inoculum (5 × 109 CFU) was deposited at the root 
of the tongue with a syringe on 2 consecutive days. Animal 
care protocol M09083 covered the experimental infection of 
dairy calves with MAP for the purpose of discovering bio-
markers of infection by metabolomic profiling and was 
approved by the Health Sciences Animal Care Committee of 
the University of Calgary.
Lipidomics
Serum samples were vortexed with 1 mL of methanol con-
taining stable isotope internal standards.19–21 Next, 1 mL of 
water and 2 mL of methyl-tert-butyl ether were added and 
the tubes vigorously shaken at room temperature for 30 min 
prior to centrifugation at 4000 xg for 10 min at room temp. 
The upper organic layer was isolated and dried by centrifu-
gal vacuum evaporation and dissolved in isopropanol: meth-
anol: chloroform (4:2:1) containing 7 mM ammonium 
acetate. The stable isotope internal standards included [2H31]
PtdE 34:1, [2H54]PtdE 28:0, [2H31]PtdC 34:1, [2H54]PtdC 
28:0, and bromocriptine as internal standards.
Direct infusion lipidomics utilized high-resolution data 
acquisition, with an orbitrap mass spectrometer (Thermo Q 
Exactive). In negative ion electrospray ionization (ESI), the 
anions of ethanolamine plasmalogens (PlsE), phosphatidyle-
thanolamines (PtdE), lysophosphoethanolamines (LPE), 
lysophosphatidic acids (LPA), sphingosine 1-phosphate (S-1-
P), phosphatidylglycerols (PG), phosphatidylinositols (PI), 
and phosphatidylserines (PS). In positive ion ESI, the cations 
of choline plasmalogens (PlsC), phosphatidylcholines (PtdC), 
lysophosphatidylcholines, and sphingomyelins were quanti-
tated. The cations and anions of bromocriptine were used to 
monitor for potential mass axis drift. Between injections, the 
transfer line was washed with successive 500 µL washes of 
methanol and hexane/ethyl acetate/chloroform (3:2:1). The 
monitored ions and parts per million error for altered phos-
phocholine-containing lipids is presented in Table 1.
Statistical analysis
Semi-quantitative data are presented as R values which rep-
resent the ratio of endogenous lipid peak area to the peak 
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area of an appropriate internal standard. A Student’s t-test 
(Microsoft Excel) was used to determine significant differ-
ences in serum levels of metabolites between MAP-infected 
animals and controls.
Results
Pilot lipidomics study: preliminary determination 
of decrements in choline-containing lipids
In our pilot study of three control and three infected cat-
tle, we found small to no changes in the serum levels of 
PG, PS, PI, PtdE, and PlsE (data not shown). However, 
we noted significant and consistent decreases in the cir-
culating pools of PtdC, PlsC, and sphingomyelins. Plots 
of these decreases for 36:1 to 36:6 PlsC, 38:1 to 38:6 
PtdC, and 16:1 to 24:1 sphingomyelins are presented in 
Figure 1.
Validation lipidomics study: validation of 
decrements in choline-containing lipids
In a follow-up study of 12 control and 12 infected cattle, we 
similarly observed specific decrements in the levels of cho-
line-containing glycerophospholipids and sphingolipids in 
infected cattle. Large decrements in circulating levels of 
PtdC (Figure 2) and PlsC (Figure 3) were monitored in cattle 
demonstrating clinical signs of MAP infection.
With regard to phosphatidylcholine metabolites, lysophos-
phatidylcholines were decreased while their phospholipase D 
Table 1. Exact masses, calculated cations, and the ppm mass 
error for the cations monitored by high-resolution mass 
spectrometry for PtdC and SM.
Biomarker Exact mass [M + H]+ ppm
PtdC 38:1 815.6404 816.6477 0.31
PtdC 38:2 813.6248 814.6320 0.84
PtdC 38:3 811.6091 812.6164 2.18
PtdC 38:4 809.5935 810.6007 4.85
PtdC 38:5 807.5778 808.5851 5.96
PtdC 38:6 805.5622 806.5694 3.04
PtdC 40:3 839.6404 840.6477 0.24
PtdC 40:4 837.6248 838.6320 0.70
PtdC 40:5 835.6091 836.6164 1.49
PtdC 40:6 833.5935 834.6007 1.49
PtdC 40:7 831.5778 832.5851 1.74
PtdC 40:8 829.5622 830.5694 0.92
PlsC 36:1 771.6141 772.6214 0.36
PlsC 36:2 769.5985 770.6058 0.52
PlsC 36:3 767.5829 768.5902 0.96
PlsC 36:4 765.5673 766.5746 1.48
PlsC 36:5 763.5517 764.5590 1.54
PlsC 36:6 761.5361 762.5434 0.98
PlsC 38:3 795.6142 796.6215 0.19
PlsC 38:4 793.5986 794.6059 0.48
PlsC 38:5 791.5829 792.5902 0.65
PlsC 38:6 789.5673 790.5746 0.60
*PlsC 38:7 787.5517 788.5589 0.58
PlsC 38:8 785.5360 786.5433 0.30
SM 16:1 700.5519 701.5592 0.54
SM 17:0 716.5832 717.5905 1.1
SM 18:0 730.5989 731.6062 0.99
SM 18:1 728.5832 729.5905 1.72
SM 24:0 814.6928 815.7001 0.78
SM 24:1 812.6772 813.6845 1.29
ppm: parts per million mass error; PtdC: phosphatidylcholines; PlsC: 
choline plasmalogens; SM: sphingomyelins.
Figure 1. Pilot lipidomics observations for MAP-positive (N = 3) 
versus MAP-negative cows (N = 3). The MAP-positive cows had 
Ct values of 24.32, 25.06, and 30.26. Data (R) are presented as 
the ratio of the peak area of the endogenous lipid to the peak 
area of the internal standard (mean ± SD).
*p < 0.01; **p < 0.05.
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(PLD) metabolites, LPA and alkyl-acyl phosphatidic acid, 
were increased (Figure 4) suggesting that PtdC are exten-
sively degraded and/or their synthesis is decreased with MAP 
infection.
Large decrements in circulating levels of sphingomyelins 
(Figure 5), another class of choline-containing lipids, were 
monitored in our non-targeted lipidomics evaluation of 
infected cattle. In the case of sphingomyelin metabolism, 
increased levels of S-1-P were monitored (Figure 5). Since 
S-1-P is both a precursor and metabolite of sphingomyelins, 
it remains to be defined if augmented sphingomyelin metab-
olism and/or decreased sphingomyelin synthesis occurs with 
PTB infection.
Time course study: decrements in  
choline-containing lipids only in cattle 
demonstrating overt clinical signs
A study of experimentally infected calves was undertaken to 
monitor the time course of lipid alterations induced by infec-
tion with MAP. Of the seven infected calves, only two devel-
oped clinical signs of Johne’s disease by 16 months. The 
group as a whole did not demonstrate any alterations in the 
levels of choline-containing lipids (Figure 6) with only one 
of the two cows demonstrating clinical signs having decre-
ments in lipid levels at 16 months (35% decrease in PtdC, 
50% decrease in PlsC, 31% decrease in sphingomyelins).
Discussion
Bacterial infection of the ileal mucosa and lymph nodes by 
MAP results in the development of a chronic granulomatous 
inflammation but only after a long (months to years) incuba-
tion period in cattle. After this long preclinical phase, com-
positional and functional changes in the gut microbiota,4 
along with a shift to a Th2-biased immune response results in 
lesions of the intestinal epithelium5,22 and liver.6,7 The 
expressions of clinical signs at this stage include treatment-
resistant diarrhea, muscle wasting, and decreased milk pro-
duction.2,3 This phase of the infection has devastating effects 
on the health of dairy herds and significant negative econom-
ical impact.
A number of “omics” technologies have been utilized in 
an attempt to define biomarkers of early disease expression. 
Figure 2. Plasma levels of phosphatidylcholines in PTB positive 
versus negative cows (N = 12 per group). Data (R) are presented 
as the ratio of the peak area of the endogenous lipid to the peak 
area of the internal standard (mean ± SEM).
p values are presented in the brackets.
Figure 3. Plasma levels of choline plasmalogens in PTB positive 
versus negative cows (N = 12 per group). Data (R) are presented 
as the ratio of the peak area of the endogenous lipid to the peak 
area of the internal standard (mean ± SEM).
p values are presented in the brackets.
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These include metabolomics studies10 of amino acids and 
metabolic intermediates that have pointed to alterations in 
the gut microbiome while proteomics studies have observed 
a general hypoproteinemia, late in the disease process.7–9 At 
this stage of the disease, there is widespread destruction of 
the mucosal wall of the small intestine and bacterial spread 
to the uterus, mammary gland, muscle, and liver.22,23 Elevated 
liver and muscle enzymes6,7 also are reflective of liver dam-
age and muscle wasting, respectively. Altered liver immune 
function is further supported by elevations in the levels of 
circulating acute phase reactants.8
Our lipidomics data from cows demonstrating clinical 
signs reveal a profound decrease in the circulating levels of 
choline-containing glycerophospholipids and sphingolipids. 
The major anatomical sites that supply these lipids to the 
bloodstream are the liver and ileal epithelium.17,18 Disruption 
of the gut wall will both decrease the absorption of glycer-
ophospholipid and sphingolipid precursors and disrupt the 
synthetic capacity of the GI epithelium to synthesize these 
lipids. Similarly, with liver lesions in MAP-positive ani-
mals,7 the biosynthesis of structural lipids will be negatively 
affected. The GI epithelium and the liver are the major 
sources of circulating glycerophospholipids and sphingolip-
ids and the dysfunction at these anatomical sites can explain 
the decrements in choline-containing lipids that we moni-
tored. In addition, the absorption of choline from the GI tract 
may be decreased and altered GI microflora may result in 
altered metabolism of choline within the gut.
It should also be noted that MAP has a cell wall rich in 
complex lipids and waxes containing mycolic acid.15 It is 
possible that reduction of some of these lipids in the cattle 
could be due to the fact that the MAP cell wall requires high 
amount of these lipids for maintaining the cell wall and for 
replication.
In our time course study, no alterations in the circulating 
levels of choline-containing lipids were detected in the early 
phases of the disease and of the two cows demonstrating 
clinical signs at the end of the 17-month study, only one was 
advanced enough for us to monitor decreases in the choline-
containing lipids. These data support the concept that 
Figure 4. Plasma levels of lysophosphatidylcholines (LPC), 
alkyl-acyl phosphatidic acid 34:0 (PeA), and lysophosphatidic acids 
(LPA) in infected versus negative cows (N = 12 per group). Data 
(R) are presented as the ratio of the peak area of the endogenous 
lipid to the peak area of the internal standard (mean ± SEM).
p values are presented in the brackets.
Figure 5. Plasma levels of sphingomyelins and sphingosine 
1-phosphate (S-1-P) in PTB positive versus negative cows (N = 12 
per group). Data (R) are presented as the ratio of the peak area 
of the endogenous lipid to the peak area of the internal standard 
(mean ± SEM).
p values are presented in the brackets.
Figure 6. Serum levels of phosphatidylcholine (PtdC) 36:4 in 
experimentally infected (N = 7) and control cows (N = 6) from 
time zero and 1 to 16 months post-infection. Data (R) are 
presented as the ratio of the peak area of the endogenous lipid to 
the peak area of the internal standard (mean ± SEM).
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disruption of the gut mucosa and liver are responsible for the 
observed serum lipid changes in cows demonstrating clinical 
signs. However, our lipidomics data do not provide any indi-
ces for the early detection of infection.
With the lack of effective vaccines or therapy for late-
stage infections, control of MAP infection involves herd 
management strategies. Therefore, it is imperative to increase 
our understanding of the risk factors for MAP infection if 
new therapies are to be developed. In this regard, polymor-
phisms in SLC11A1 represent a significant risk factor for 
MAP infection.24–27 SLC11A1 is a divalent metal ion trans-
porter family with polymorphisms having the potential to 
alter the levels of metal ions essential for the activity of a 
number of enzymes. In this regard, PLD which is activated 
by divalent metal ions28 hydrolyzes PtdC and lysophosphati-
dylcholines to generate phosphatidic acids (PA) and LPA, 
respectively. In our lipidomics analyses, we did not monitor 
circulating levels of diacyl-phosphatidic acids in control or 
infected cows. However, we did monitor significant increases 
in alkyl-acyl phosphatidic acid 34:0 and LPA 16:0 and 18:0 
(Figure 4). These data, in conjunction with the decreased 
levels of the direct precursors of each of these metabolites, 
suggest that abnormal SLC11A1 function may contribute to 
the monitored decrements in serum choline-containing 
lipids.
Our observations also may be of significance to human 
health. There is increasing concern that MAP may be a 
zoonotic bacterium29 that contributes to the development of 
Crohn’s disease30,31 and multiple sclerosis.32 Furthermore, 
multiple sclerosis patients with MAP infection31 and Crohn’s 
disease patients with MAP infection33 possess polymor-
phisms in SLC11A1. While these may represent a small sub-
set of patients with these diseases, it suggests that the 
contribution of MAP infections to the disease process in 
patients with SLC11A1 polymorphisms should be investi-
gated further.
This pilot study is only limited by the small sample size. 
The next steps would be to investigate a larger cohort of cat-
tle and to include analysis of SLC11A1 polymorphisms to 
evaluate any possible correlation with alterations in choline-
containing lipids.
Conclusion
MAP infection in cows can result in dysfunctional host-GI 
flora interactions and frank lesions of the gut mucosa and 
liver. These dysfunctions ultimately result in the emergence 
of clinical signs. Our lipidomics data suggest that at this 
phase of the disease, tissue pathologies lead to large-scale 
decrements in the biosynthesis of essential choline-contain-
ing glycerophospholipids and sphingolipids. The contribu-
tion of SLC11A1 polymorphisms to altered lipid metabolism 
requires further investigation, including in Crohn’s disease 
and multiple sclerosis patients with SLC11A1 polymor-
phisms. Our data also suggest that choline supplementation 
may be worthy of investigation in MAP-positive cows.
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